Updated Oct 9, 2026 · 05:00 UTC

RXRXRecursion Pharmaceuticals, Inc.

Health Care · United States · XNAS · biological products, (no diagnostic substances)

$3.95−7.49%last session · market closed

Market cap

$2.12b

real-world

Tokenized

$4k

<0.001% of the asset

Avg token price

$3.94

−0.20% vs real

Spot volume, 24h

1 venues

Derivatives, 24h

—

Perp open interest

—

In DeFi

—

RXRX · Price

Sep 12, 2026low $3.19 · high $4.77 · now $4.64Oct 7, 2026

Token Real

Earnings

Nasdaq’s earnings calendar

Next earnings

Nov 4

estimated date · Sep 2026 quarter · EPS forecast −$0.24 (3 analysts)

Last earnings, Aug 5

−$0.25 EPS

−8.7% vs −$0.23 forecast · Jun 2026 quarter

Real market

Recursion Pharmaceuticals, Inc. Class A Common Stock

Last close

$4.27

Oct 7

Traded on Oct 7

$178.5m

Price now

$3.95

market closed

Where it trades

24h volume by venue, as the exchanges report it · open interest and funding on the perpetuals

Spot · $6 · 1 venue

Ondo Stocks1 pair$6

Derivatives · — · 0 venues

None yet

Onchain versions

1 token from 1 issuer

RXRXonOndo Assets$3.94$4k

By chain

Where the tokens circulate, issuers’ unsold stock taken off

Ethereum70%$3k

BNB Chain30%$1k

In DeFi

Pools and lending markets that hold these tokens

None found

Business 12 months to Jun 2026 · SEC EDGAR

Results

Revenue

$54.9m

−15% YoY

Operating income

−$544.0m

-992% margin

Net income

−$518.9m

-946% margin

EPS, diluted

−$0.97

Cash and balance sheet

Free cash flow

−$352.3m

−642% of revenue

Net cash

$540.9m

$545.7m cash and securities, $4.8m debt

Diluted shares

532m

+28% YoY

Valuation at today’s market cap

EV / sales

28.7×

enterprise value $1.58b

10-Q filed Aug 5, 2026 ↗

Quarterly

RevenueNet income